<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02908906</url>
  </required_header>
  <id_info>
    <org_study_id>CR108223</org_study_id>
    <secondary_id>2016-002017-22</secondary_id>
    <secondary_id>63723283LUC1001</secondary_id>
    <nct_id>NCT02908906</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers</brief_title>
  <official_title>A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for&#xD;
      JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in&#xD;
      participants with selected advanced cancers including non-small-cell lung cancer (NSCLC),&#xD;
      melanoma, renal, bladder, small-cell lung cancer (SCLC), gastric/esophageal cancer, and&#xD;
      high-level microsatellite instability (MSI-H) or mismatch repair-deficient (dMMR) colorectal&#xD;
      cancer (CRC) in Part 2 and to determine one or more additional RP2Ds (Part 3 and Part 4).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a First in Human (FIH), open-label (all people involved know the identity of the&#xD;
      intervention), multicenter (more than 1 study site) study in participants with advanced&#xD;
      cancers to establish the recommended Phase 2 dose (RP2D[s]) with IV administration for&#xD;
      JNJ-63723283 in Part 1, to evaluate the safety and efficacy of the IV RP2D(s) in Part 2 and&#xD;
      to determine one or more additional RP2Ds in Parts 3 and 4. Participant participation will&#xD;
      include a Screening Phase (28 Days) during which participant eligibility will be reviewed&#xD;
      prior to administration of the first dose of JNJ-63723283; a Treatment Phase that will start&#xD;
      at the first dose and continue until treatment is discontinued; and a Survival Follow-up&#xD;
      Phase (applicable for Part 1 and 2) starting upon completion of the End-of-Treatment Visit&#xD;
      and ends when the participant completes or withdraws from the study. The end of the study is&#xD;
      defined as last study assessment for the last participant on study or if the sponsor&#xD;
      terminates the study, whichever comes first. Participants safety will be monitored throughout&#xD;
      the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2016</start_date>
  <completion_date type="Anticipated">January 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 12, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Frequency and Severity of Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>Frequency and severity of dose-limiting toxicity will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Subjects With Selected Advanced Solid Tumors</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>Objective Response Rate (ORR) is defined as percentage of subjects with best objective response of complete response (CR) or partial response (PR) based on Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve from Time Zero to Dosing Interval (AUC [0-tau])</measure>
    <time_frame>Up to 2 years and 5 months</time_frame>
    <description>AUC (0-tau) is defined as area under the serum concentration versus time curve from time zero to dosing interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) as a Measure of Safety</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant administered a investigational or non-investigational medicinal product. An AE does not necessarily have a causal relationship with the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The Cmax is the maximum observed serum concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Area Under the Serum Concentration Versus Time Curve Between time t1 and t2 (AUC [t1-t2])</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>AUC (t1-t2) is defined as the area under the serum concentration versus time curve between time t1 and t2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 3: Elimination Half-Life (t1/2)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The elimination half-life (t1/2) is the time measured for the serum concentration to decrease by 1 half to its original concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Total Systemic Clearance of (CL)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>Total systemic Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Volume of Distribution at Steady-State (Vss)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The Vss is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of JNJ-63723283 at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1, 2 and 4: Accumulation Ratio (R)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The R is obtained by dividing AUC at two different time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 3 and 4: Area Under the Serum Concentration Versus Time Curve Between Time Zero and Time t (AUC [0-t])</measure>
    <time_frame>Up to 2 years and 5 months</time_frame>
    <description>AUC (0-t) is defined as area under the serum concentration versus time curve between time zero and time t.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 3: Area Under the Serum Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-Infinity])</measure>
    <time_frame>Up to 2 years and 5 months</time_frame>
    <description>AUC (0-infinity) is defined as area under the serum concentration versus time curve from time zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 3 and 4: Concentration just Prior to the Beginning of at the end of a Dosing Interval (Ctrough)</measure>
    <time_frame>Up to 2 years and 5 months</time_frame>
    <description>Ctrough is defined as the concentration just prior to the beginning of at the end of a dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Anti-JNJ-63723283 Antibodies and Effect on Serum JNJ-63723283 Concentrations</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>Serum samples will be analyzed for antibodies to JNJ-63723283. The titer of the confirmed positive samples will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) per Immune-Related Response Criteria (irRC)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>ORR is defined as percentage of subjects with best objective response of complete response (CR) or partial response (PR) based on irRC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST v1.1</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>For Participants who achieve CR or PR, DOR will be calculated as time from initial response of CR or partial response (PR) to progressive disease or death due to underlying disease whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per irRC</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>For Participants who achieve CR or PR (defined by irRC), DOR will be calculated as time from initial response of CR or partial response (PR) to progressive disease or death due to underlying disease whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR) per RECIST v1.1</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The CBR is defined as the percentage of participants who achieve CR, PR or stable disease (SD; greater than or equal to [&gt;=] 24 weeks from the 1st study drug) based on RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate per irRC</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The CBR is defined as the percentage of participants who achieve CR, PR or SD (&gt;= 24 weeks from the 1st study drug) based on irRC criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per RECIST v1.1</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The time from first dose of JNJ-63723283 to progressive disease as defined by RECIST v 1.1 or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per irRC</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The time from first dose of JNJ-63723283 to progressive disease as defined by irRC or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Approximate 2.5 years</time_frame>
    <description>The time from first dose of JNJ-63723283 to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>JNJ-63723283</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part 1, the first cohort will receive JNJ-63723283 at a starting dose of 80 milligram (mg), IV every 2 weeks. JNJ-63723283 doses will be escalated following a modified Continual Reassessment Method (mCRM). Multiple doses, dose administration routes (subcutaneous [SC] or IV), and dose schedules may be explored. In Part 2, participants will receive JNJ-63723283 at the recommended Phase 2 dose (RP2D) determined in Part 1. In Part 3, participants will receive JNJ-63723283 to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety. In Part 4, participants will receive JNJ-63723283 at the dose level determined in Part 3. Additional cohorts may be enrolled in Part 4 to evaluate additional doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-63723283</intervention_name>
    <description>JNJ-63723283 will be administered by IV infusion or SC injection or infusion.</description>
    <arm_group_label>JNJ-63723283</arm_group_label>
    <other_name>Cetrelimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1&#xD;
&#xD;
          -  Has thyroid function laboratory values within normal range&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
          -  Willing and able to adhere to the prohibitions and restrictions specified in this&#xD;
             protocol&#xD;
&#xD;
          -  Participants enrolled into Part 2 must have tumor tissue available for correlative&#xD;
             studies. Fresh tumor biopsy is preferred. Archival tissue must meet the following&#xD;
             criteria: archival sections within 4 months of sectioning that have been stored at 2&#xD;
             degree to 8 degree Celsius in the dark or archival tumor blocks within 5 years of&#xD;
             collection. Participants without tissues meeting the aforementioned archived tissue&#xD;
             criteria must undergo a fresh biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has uncontrolled intercurrent illness, including but not limited to ongoing or active&#xD;
             infection requiring IV antibiotics, symptomatic congestive heart failure (New York&#xD;
             Heart Association class III-IV), unstable angina pectoris, cardiac arrhythmia, poorly&#xD;
             controlled hypertension or diabetes, or psychiatric illness/social situation that&#xD;
             would limited compliance with study requirements&#xD;
&#xD;
          -  Has had prior treatment with an anti-Programmed-cell death receptor-1 (PD-1) antibody,&#xD;
             anti-the ligand to programmed-cell death 1 (PD-L1) antibody or anti-the ligand to&#xD;
             programmed-cell death 2 (PD-L2) antibody&#xD;
&#xD;
          -  Treatment with any local or systemic anti-neoplastic therapy, radiotherapy (excluding&#xD;
             limited palliative radiation), or investigational anticancer agent within 14 days or 4&#xD;
             halflives, whichever is longer, up to a maximum wash-out period of 28 days prior to&#xD;
             the initiation of study drug administration&#xD;
&#xD;
          -  Grade 3 or higher toxicity effects from previous treatment with immunotherapy&#xD;
&#xD;
          -  A woman who is pregnant, breast-feeding, or planning to become pregnant while enrolled&#xD;
             in this study or within 5 months after the last dose of study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giuseppe Moscati di Avellino</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia Servizio Radioterapia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS-Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Aou San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine</name>
      <address>
        <city>Chisinau</city>
        <zip>MD-2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku, II Klinika Chorob Pluc i Gruzlicy</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FSBSI 'N. N. Blokhin Russian Cancer Research Center'</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pyatigorsky Oncology Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioEk, LLC</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>City Oncology Dispensary</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>City Oncology Dispensary</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Gral. Univ. Gregorio Mara√±on</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Hm Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen de La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Univ. de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beatson West Of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Nhs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Bobby Robson Unit, Northern Centre for Cancer Care</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108223</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

